---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-139104"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:07:27.229027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Guardant Health reports Shield test 83% sensitivity, 90% specificity for CRC in ECLIPSE study at DDW

## Summary
- Shield blood test achieved 83% overall sensitivity and 90% specificity in detecting colorectal cancer in average-risk adults.
- Sensitivity of 55% for Stage I, 100% for Stages II, III, and IV; 81% for Stages I-III, 72% for localized (Stage I-II).
- Real-world adherence rate for Shield exceeds 90% since commercial launch in May 2022.
- Study enrolled diverse population: 13% Black, 15% Hispanic, 7% Asian American.
- Data suggests Shield could detect CRCs at curable stage and help close screening gap.

## SEC filing metadata
- accession: 0001193125-23-139104
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000119312523139104/0001193125-23-139104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000119312523139104/d130904d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-139104
- JSON: https://secwatch.observer/filing/0001193125-23-139104.json
- Plain text: https://secwatch.observer/filing/0001193125-23-139104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.